Mesalamine-induced lung toxicity. [Am J Gastroenterol. 1996]

SearchDatabase nameforSearch term

Advanced Search

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 1

Click to change filter selection through MyNCBI.

1: Am J Gastroenterol. 1996 May;91(5):1039-40.Links

Mesalamine-induced lung toxicity.

Bitton A, Peppercorn MA, Hanrahan JP, Upton MP.

Center for Inflammatory Bowel Disease, Beth Israel Hospital, Boston, Massachusetts, USA.

Lung toxicity associated with 5-aminosalicylate (5-ASA) agents is a rare entity. We report the case of a 32-yr-old woman with ulcerative colitis who developed progressive shortness of breath while taking one of the 5-ASA drugs, oral mesalamine. Bilateral pulmonary infiltrates, peripheral eosinophilia, and histological findings consistent with acute pneumonitis characterized the lung injury. Although the differential diagnosis is broad, mesalamine-induced lung damage must be considered in patients who develop unexplained respiratory symptoms while taking this agent.

PMID: 8633548 [PubMed - indexed for MEDLINE]

Lung disease associated with orally administered mesalamine for ulcerative colitis. [Chest. 1992]
ReviewMesalazine-induced eosinophilic pneumonia. [Respiration. 1999]
Mesalamine-induced lung injury in a patient with ulcerative colitis and a confounding autoimmune background: a case report. [Mt Sinai J Med. 2005]
Exacerbation of chronic ulcerative colitis with mesalamine. [Gastroenterology. 1995]
Review[False melanuria in a female patient treated with 5-ASA for ulcerative colitis] [Med Clin (Barc). 1995]

Patient Drug Information

Mesalamine (Asacol®, Canasa®, Pentasa®, ...) Mesalamine is used to treat ulcerative colitis (a condition in which part or all of the lining of the colon [large intestine] is swollen or worn away). Mesalamine delayed-release tablets and controlled-release capsules m...

» read more ...

Display Show

Mesalamine-induced lung toxicity.

Related Articles